Notice for vutrisiran (Alnylam Australia Pty Ltd)
Active ingredients
vutrisiran
Sponsor
Date of review outcome
Lapse date
Type
Orphan Drug
Dosage form(s)
Subcutaneous injection
Indication
Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in patients with polyneuropathy
Therapeutic area
Inherited metabolic disorders